Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma.

ABSTRACT:

Introduction

Adrenocortical carcinoma (ACC) is a rare cancer with suboptimal response to chemotherapy. The role of immunotherapy in ACC management is evolving.

Methods

An investigator-initiated, open-label, phase 2 clinical trial was performed to ascertain the activity and safety of monotherapy with pembrolizumab (a humanized monoclonal anti-programmed cell death protein 1 antibody) in patients with advanced ACC. This study was part of a basket clinical trial (ClinicalTrials.gov ID: NCT02721732). Study participants were enrolled from August 15, 2016, until December 7, 2020. Pembrolizumab (200 mg) was administered intravenously every 3 weeks. All other lines of therapy, including mitotane, were stopped before pembrolizumab initiation. The primary endpoint was the nonprogressi

SUBMITTER: Chahla B 

PROVIDER: S-EPMC12549218 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature